SI1608685T1 - Antagonisti VEGF za zdravljenje diabetesa - Google Patents

Antagonisti VEGF za zdravljenje diabetesa

Info

Publication number
SI1608685T1
SI1608685T1 SI200430312T SI200430312T SI1608685T1 SI 1608685 T1 SI1608685 T1 SI 1608685T1 SI 200430312 T SI200430312 T SI 200430312T SI 200430312 T SI200430312 T SI 200430312T SI 1608685 T1 SI1608685 T1 SI 1608685T1
Authority
SI
Slovenia
Prior art keywords
vegf
diabetes
treatment
vegf antagonists
blocking
Prior art date
Application number
SI200430312T
Other languages
English (en)
Inventor
Mark W Sleeman
Stanley J Wiegand
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SI1608685T1 publication Critical patent/SI1608685T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SI200430312T 2003-03-28 2004-03-26 Antagonisti VEGF za zdravljenje diabetesa SI1608685T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45879003P 2003-03-28 2003-03-28
PCT/US2004/009246 WO2004087206A2 (en) 2003-03-28 2004-03-26 Methods of treating diabetes by blocking vegf-mediated activity
EP04758372A EP1608685B1 (en) 2003-03-28 2004-03-26 Vegf antagonists for the treatment of diabetes

Publications (1)

Publication Number Publication Date
SI1608685T1 true SI1608685T1 (sl) 2007-08-31

Family

ID=33131825

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200430312T SI1608685T1 (sl) 2003-03-28 2004-03-26 Antagonisti VEGF za zdravljenje diabetesa

Country Status (17)

Country Link
US (1) US7052691B2 (sl)
EP (1) EP1608685B1 (sl)
JP (2) JP4730909B2 (sl)
AT (1) ATE354592T1 (sl)
AU (1) AU2004226417B2 (sl)
BR (1) BRPI0408749B1 (sl)
CA (1) CA2519787C (sl)
CY (1) CY1106530T1 (sl)
DE (1) DE602004004883T2 (sl)
DK (1) DK1608685T3 (sl)
ES (1) ES2278333T3 (sl)
HK (1) HK1080092A1 (sl)
MX (1) MXPA05008972A (sl)
PL (1) PL1608685T3 (sl)
PT (1) PT1608685E (sl)
SI (1) SI1608685T1 (sl)
WO (1) WO2004087206A2 (sl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378095B2 (en) 2004-07-30 2008-05-27 Regeneron Pharmaceuticals, Inc. Methods of treating type I diabetes by blocking VEGF-mediated activity
PL1861116T3 (pl) 2005-03-25 2016-02-29 Regeneron Pharma Formulacje antagonistów VEGF
CN101478949A (zh) 2006-06-16 2009-07-08 瑞泽恩制药公司 适合玻璃体内施用的vegf拮抗剂的制剂
ES2345596B1 (es) * 2009-03-26 2011-07-13 Fundacion Progreso Y Salud Composicion para la prevencion o el tratamiento de la diabetes mellitus.
US20100330098A1 (en) * 2009-06-29 2010-12-30 Kuo Calvin J Methods to regulate glucose metabolism
EP4360709A3 (en) 2011-01-13 2024-07-03 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
WO2015110067A1 (zh) 2014-01-25 2015-07-30 成都康弘生物科技有限公司 一种抑制血管新生或生长的融合蛋白及其用途
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
MA40354A (fr) 2014-07-18 2017-05-24 Sanofi Sa Procédé permettant de prédire le résultat d'un traitement avec de l'aflibercept d'un patient suspecté de souffrir d'un cancer
CN108712911A (zh) 2015-12-30 2018-10-26 科达制药股份有限公司 抗体及其缀合物
ITUB20169928A1 (it) * 2016-01-12 2017-07-12 Medical And Biotechnological Services In Sigla M B S Srl Formulazioni farmaceutiche per il trattamento del diabete
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9410533D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd In situ hybridisation and immuno-Chemical localisation of a growth factor
KR100816572B1 (ko) * 1999-04-28 2008-03-24 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 항-ｖｅｇｆ 항체 및 이를 포함하는 약제학적 조성물
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
ATE293164T1 (de) 1999-06-08 2005-04-15 Regeneron Pharma Modifizierte chimärische polypeptide mit verbesserten pharmakokynetischen eigenschaften

Also Published As

Publication number Publication date
CA2519787A1 (en) 2004-10-14
US20040213787A1 (en) 2004-10-28
DK1608685T3 (da) 2007-06-11
MXPA05008972A (es) 2005-11-04
CA2519787C (en) 2012-06-05
PL1608685T3 (pl) 2007-07-31
WO2004087206A3 (en) 2004-12-16
AU2004226417A1 (en) 2004-10-14
BRPI0408749B1 (pt) 2016-10-04
JP2011037894A (ja) 2011-02-24
ES2278333T3 (es) 2007-08-01
EP1608685B1 (en) 2007-02-21
AU2004226417B2 (en) 2009-01-22
US7052691B2 (en) 2006-05-30
JP2006521397A (ja) 2006-09-21
BRPI0408749A (pt) 2006-03-28
WO2004087206A2 (en) 2004-10-14
HK1080092A1 (en) 2006-04-21
JP4730909B2 (ja) 2011-07-20
PT1608685E (pt) 2007-05-31
DE602004004883D1 (de) 2007-04-05
ATE354592T1 (de) 2007-03-15
EP1608685A2 (en) 2005-12-28
DE602004004883T2 (de) 2007-11-15
CY1106530T1 (el) 2012-01-25

Similar Documents

Publication Publication Date Title
HK1080092A1 (en) Vegf antagonists for the treatment of diabetes
HK1105167A1 (en) Methods of treating type i diabetes by blocking vegf-mediated activity
ATE321048T1 (de) Beta-amino-tetrahydroimidazo(1,2-a)pyrazine und - tetrahydrotriazolo(4,3-a)pyrazine als dipeptidyl peptidase inhibitoren zur behandlung oder prevention von diabetes
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
MXPA05010819A (es) Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
WO2006023649A3 (en) Treatment of severe multiple sclerosis
ATE435015T1 (de) Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
MY151032A (en) Treatment of tnf? related disorders
WO2004105757A3 (en) Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
EA200801118A1 (ru) Способ ингибирования flt3 киназы
WO2005107726A3 (en) Method for the treatment of back pain
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
TW200716673A (en) Use of TNF &ahr; inhibitor for treatment of erosive polyarthritis
WO2004084943A8 (en) Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
WO2007073497A3 (en) Calcium channel antagonists
WO2007075852A3 (en) Calcium channel antagonists
MXPA05001649A (es) Uso de compuestos antagonistas del cgrp para tratamiento de la psoriasis.
ATE555803T1 (de) Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen
ATE520709T1 (de) Campylobacter-polypeptide und verwendungsverfahren
WO2006060787A3 (en) Delaying or preventing onset of multiple sclerosis
WO2003037310A3 (en) Use of inhibitors of the abc drug transporter to increase the activity of anti-microbial agents
WO2004009773A3 (en) Methods and compositions for activating or inhibiting vegf-d and vegf-c
WO2006016192A3 (en) Combination therapy with nk3 receptor antagonists for the treatment of schizophrenia
DE60214019D1 (de) Stickstoff enthaltende heterozyklen und ihre verwendung als raf inhibitoren
ATE533769T1 (de) Als kinaseinhibitoren geeignete pyrrolotriazinverbindungen